Physician

Varun Choudary Dhulipala, M.D.

According to 2025 Medicare claims, Varun Dhulipala, M.D. (NPI: 1902196165) practices hematology in the Nashville-Davidson--Murfreesboro--Franklin, TN market, with the plurality of this provider's patient population coming from Maury, TN. This provider's primary affiliated billing organization is TENNESSEE ONCOLOGY PLLC (NPI: 1811955917; TIN: 621647259) and primary practice location at 38401-4338. Dhulipala is affiliated with the MID-TENNESSEE COMMUNITY ACO LLC (ACO ID: A5543), participating under the MSSP model.

Dhulipala's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 765 traditional Medicare patients, billed 192,969 HCPCS/CPT codes, and received $4,250,936 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,105 prescription claims across 363 beneficiaries totaling $4,378,612 in drug costs, led by Cabometyx (Cabozantinib S-Malate). DME data shows 36 claims. Open Payments data shows 117 records totaling $2,723. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $15,333 to $4,250,936. Similarly, Part D prescription costs have moved sharply higher in recent years, from $8,569 to $4,378,612. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	79	398	$15,333
2018	264	2,244	$89,900
2019	365	3,358	$142,198
2020	393	3,127	$144,298
2021	462	3,849	$218,499
2022	524	3,656	$169,293
2023	585	83,685	$1,464,707
2024	765	192,969	$4,250,936

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	17	32	$8,569
2016	19	36	$1,529
2017	26	57	$31,837
2018	114	655	$581,816
2019	181	992	$704,414
2020	209	1,314	$1,506,003
2021	277	1,708	$1,889,251
2022	307	1,758	$2,024,622
2023	342	2,016	$3,307,559
2024	363	2,105	$4,378,612

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	41	$2,921
2021	N/R	64	$5,299
2022	N/R	72	$3,120
2023	N/R	23	$4,272
2024	N/R	36	$629

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	378	672	$84
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	362	593	$12
80053	Blood test, comprehensive group of blood chemicals	442	1,463	$10
36415	Insertion of needle into vein for collection of blood sample	554	1,977	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	565	2,258	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Cabometyx	Cabozantinib S-Malate	20	600	$491,702
Brukinsa	Zanubrutinib	34	1,020	$491,552
Revlimid	Lenalidomide	26	728	$464,107
Calquence	Acalabrutinib Maleate	22	660	$339,482
Imbruvica	Ibrutinib	21	588	$313,395

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	11	$278
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	11	$188
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	14	$163

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	117	$2,723	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Varun Choudary Dhulipala, M.D.?

Tedicare shows public-source Medicare data for Varun Choudary Dhulipala, M.D. (NPI 1902196165), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Varun Choudary Dhulipala, M.D. have ACO affiliation data?

Varun Choudary Dhulipala, M.D. is shown with ACO affiliation data for MID-TENNESSEE COMMUNITY ACO LLC (MSSP, ACO ID A5543).

What billing organization is linked to Varun Choudary Dhulipala, M.D.?

Varun Choudary Dhulipala, M.D. is linked to TENNESSEE ONCOLOGY PLLC (billing NPI 1811955917) in the available physician profile data.

Does Varun Choudary Dhulipala, M.D. have Open Payments data?

Varun Choudary Dhulipala, M.D. has 117 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.